Covaxin Overall 77.8% Effective, Claims Bharat Biotech In Phase 3 Data

The vaccine offers "65.2 per cent protection" against the new Delta variant, said to be highly infectious, Bharat Biotech said.

Bharat Biotech's Covaxin is overall 77.8 per cent effective against Covid, the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed. COVAXIN® Proven SAFE in India's Largest Efficacy Trial. Final Phase-3 Pre-Print Data Published on https://t.co/JJh9n3aB6Vpic.twitter.com/AhnEg56vFN The vaccine offers "65.2 per cent protection" against the new Delta variant, said to be highly infectious, it said. "We are proud to put India on the global map with scientific conviction, competence and commitment. Covaxin scores 10 world-class publications endorsing Innovation, clinical research, data, safety, efficacy. Thank collaborators & Positive BB teamwork enduring a pandemic (sic)," Bharat Biotech co-founder Suchitra Ella said in a late-night tweet. In a statement, the vaccine maker further said, "Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group."